In this section
- 3Rs research funding
- Funded 3Rs research
- Funding in 2009
- Funding in 2008
- Funding in 2007
- Funding in 2006
- Funding in 2005
- Funding in 2004
- Professor Aziz, Queen Mary, University of London
- Dr Michael Emerson, Imperial College London
- Dr Berthold Gottgens, University of Cambridge
- Dr Majid Hafezparast, University of Sussex
- Dr Susan Jobling, Brunel University
- Professor Mark Lewis, University of Bedfordshire
- Prof Mackenzie, Barts and The London School of M&D
- Dr Kevin Moffat, University of Warwick
- Professor Hugh Perry, University of Southampton
- Dr Johnny Roughan, Newcastle University
- Dr Vasanta Subramanian, University of Bath
- Professor Susan Watson, University of Nottingham
- Dr R Williams, Royal Holloway University of London
- Professor Sue Barnett, University of Glasgow
- Professor Andrew Cossins, University of Liverpool
- Dr Atticus Hainsworth, St George's London
- Dr Ioanna Katsiadaki, Cefas
- Professor Robert Newbold, Brunel University
- Dr N G Coldham, Veterinary Laboratories Agency
- Professor D E Davies, University of Southampton
- Professor J A Davies, University of Edinburgh
- Professor C R Wolf, University of Dundee
- Dr A J Grierson, University of Sheffield
- Dr M Guille, University of Portsmouth
- Dr W Hope, University of Manchester
- Dr P Jones, Hutchison/MRC Research Centre
- Professor P M Jones, King's College London
- Dr A MacNicoll, Central Science Laboratory
- Dr G Woodhall, Aston University
- Dr Fullwood, Lancaster University
- Dr Emerson, Imperial College London
- Professor Perry, University of Southampton
- Professor Baker, University of Newcastle
- Dr Walmsley, University of Manchester
- Dr Xing, NIBSC
- Professor Harding, Imperial College London
- Dr Thompson, Central Science Laboratory
- Dr Sloan, Cardiff University
- Professor Thomas, Cardiff University
- Professor Wolf, CXR Biosciences Ltd
- Dr Tucker, University of Cambridge
- Dr Turrell, Fisheries Research Services
- Dr Redhead, Intervet UK Ltd
- Dr Smith, University of Sheffield
- Professor Ward, Keele University
- Professor Lemon, University College London
- Dr Roughan, University of Newcastle
- Professor Bibby, University of Bradford
- Professor Nicol, University of Bristol
- Dr Keith Redhead, Intervet UK Ltd
- Dr Paul Simons, University College London
- Professor Phil Stephens, Cardiff University
- Professor Sriskandan, Imperial College London
- Dr Jun Zou, University of Aberdeen
- Professor Baker, Queen Mary, University of London
- Professor Barclay, Imperial College London
- Dr Brennan, Queen Mary, University of London
- Dr Chesler, Institute of Cancer Research
- Professor Harding, Imperial College London
- Professor Hogstrand, King's College Londo
- Dr Hohenstein, MRC Human Genetics Unit
- Professor Howard, University of Ulster
- Dr Roland Jones, University of Bath
- Dr Nassar, University of Sheffield
- Dr Sansom, University of Glasgow
- Professor Secombes, University of Aberdeen
- Dr Sesardic, NIBSC
- Studentships
- Funded studentships
- Strategic awards
- NC3Rs / LASA Small Awards Scheme
- NC3Rs transfer to Je-S
|
Dr Walmsley, University of Manchester
Development of a new human cell genotoxicity assay to reduce the use of live animals in drug development Aims Safety testing of new pharmaceuticals includes screening for the potential to cause cancer. Compounds that test negative in the in vitro regulatory genotoxicity tests then go on to rodent testing. The existing mammalian cell in vitro tests are highly sensitive so most carcinogens are identified, but many safe compounds are falsely identified as potential carcinogens. Because this can lead to needless loss of useful new drugs, the live animal tests are still conducted when there is only one in vitro positive result. By using a new high specificity human cell-based genotoxicity test, the aim will be to reduce the number of compounds tested on animals. Methods Preliminary studies with a new human cell genotoxicity test have revealed high specificity and sensitivity in detecting representative chemicals from all types of genotoxin. Some of the compounds (promutagens) are only carcinogenic after passing through the liver, so it is proposed to develop the test in a liver cell line to give a better indication of the genotoxicity. This will be compared with the results of the existing tests using liver extracts, which are currently required by the regulators. Implications for the 3Rs The test will be a valuable new tool to confirm positive regulatory data from existing tests and with fewer numbers of compounds going on to animal tests, there will be a reduction in the numbers used. If successful, this will also avoid the considerable costs of carrying out animal tests. Publications - Jagger C, Tate M, Cahill PA, Hughes C, Knight AW, Billinton N & Walmsley RM (2009) Assessment of the genotoxicity of S9-generated metabolites using the GreenScreen HC GADD45a-GFP assay. Mutagenesis 24 (1), 35-50
Read the abstract - Walmsley RM (2008) Gadd45a-GFP GreenScreen HC genotoxicity screening assay. Expert Opinion in Drug Metabolism and Toxicology 4 (6), 827-835
Read the abstract
|
|
Return to top
